Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacopsychiatry. 2005 Jan;38(1):20-3.

Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.

Author information

1
UMC St Radboud Nijmegen, Unit for Clinical Psychopharmacology and Neuropsychiatry, 6500 HB Nijmegen, The Netherlands. k.grootens@psy.umcn.nl

Abstract

BACKGROUND:

The availability of new atypical antipsychotics provides new opportunities for the treatment of borderline personality disorder (BPD).

METHODS:

Original papers on this topic were sought. Our study reviewed and discussed 14 papers.

RESULTS:

2 RCTs, 4 non-controlled open-label studies and 8 case reports. The patient populations studied were highly diverse and the dropout rate after a long follow-up period was high. All of the articles reported positive effects of olanzapine, clozapine, quetiapine and risperidone.

CONCLUSION:

BPD patients with psychotic-like, impulsive or suicidal symptoms might benefit from atypical antipsychotics. Since the methodological quality of the reviewed articles is poor, further randomised placebo-controlled studies with longer follow-ups are needed before any firm conclusions can be drawn.

PMID:
15706462
DOI:
10.1055/s-2005-837767
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Georg Thieme Verlag Stuttgart, New York
    Loading ...
    Support Center